Altered strategy of prophylactic anti‐D administration in pregnancy to cover term and post‐term – a pilot study
Authors:
Open Access
- 27 March 2021
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 116 (9) , 1005-1011
Abstract
Background and objective Routine antenatal anti‐D prophylaxis (RAADP) to RhD‐negative women is most often administered in gestational age (GA) 28–30 weeks with the next anti‐D dose administered postpartum. The aim of this study was to analyse the proportion of RhD‐negative women where RAADP is not detectable at term and in a pilot study to investigate whether RAADP administered in GA 28 and 38 results in detectable levels at term, post‐term and post‐delivery. Materials and methods In a retrospective analysis, 4280 RhD‐negative women carrying an RHD positive fetus were included and the proportion with a negative antibody screen at delivery was determined. In the second part, 39 pregnancies were included prospectively, a second dose of RAADP was administered in GA 38 weeks, and anti‐D was quantified before the second dose and then weekly for 5 weeks. Results In the retrospective analysis, 20·5% (856/4280) with RAADP administered in GA 28 were negative in routine antibody screening at delivery. In the small prospective study, 18% (7/39) had a negative antibody screen and 26% (10/39) had levels below 0·005 IU/ml, in the quantification assay, in GA 38. Anti‐D prophylaxis administered in GA 38 showed detectable levels of anti‐D up to 30 days post‐delivery, with concentration at delivery 0·060 ± 0·034 IU/ml (mean ± SD). Conclusion Approximately 20% of the RhD‐negative women show non‐detectable levels of anti‐D at term. A second dose of RAADP at GA 38 results in stable concentrations of anti‐D at term, post‐term and post‐delivery, but with large interindividual variation.Keywords
Funding Information
- Stockholms Läns Landsting (FOU 2018‐2019)
This publication has 22 references indexed in Scilit:
- Targeted Routine Antenatal Anti-D Prophylaxis in the Prevention of RhD Immunisation - Outcome of a New Antenatal Screening and Prevention ProgramPLOS ONE, 2013
- Fetomaternal hemorrhage in normal vaginal delivery and in delivery by cesarean sectionTransfusion, 2012
- Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and QualityPLOS ONE, 2012
- Routine antenatal anti‐D prophylaxis – is the protection adequate?Transfusion Medicine, 2011
- Risk factors for the presence of non‐rhesus D red blood cell antibodies in pregnancy*BJOG: An International Journal of Obstetrics & Gynaecology, 2009
- Management of Rhesus Alloimmunization in PregnancyObstetrics & Gynecology, 2008
- General obstetrics: The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti‐D immunoglobulinBJOG: An International Journal of Obstetrics & Gynaecology, 2005
- The estimation of fetomaternal haemorrhageTransfusion Medicine, 1999
- Fetomaternal hemorrhage: incidence, risk factors, time of occurrence, and clinical effectsTransfusion, 1990
- Fetomaternal Transplacental Hemorrhage during Pregnancy and after DeliveryVox Sanguinis, 1986